T W O D E C A D E S, O N E M E S S A G E : P R E V E N T I O N M AT T E R S
|
|
- Samson Osborne
- 5 years ago
- Views:
Transcription
1 V 7 YEARS AND COUNTING... VI IV III II AVAC? 4 to an AIDS Vaccine? 3 2 AIDS VACCINE ADVOCACY COALITION MAY 2001 AIDS VACCINE ADVOCACY COALITION MAY HOW DO YOU FIGHT A DISEASE OF MASS DESTRUCTION...? C1 AVA C R E P O RT AND OTHER QUESTIONS ON THE ROAD TO AN AIDS VACCINE. FINLAND RUSSIA UNITED KINGDOM NETHERLANDS BELGIUM GERMANY CANADA FRANCE SWITZERLAND ITALY SCIENCE, URGENCY, AND COURAGE VII CAN A SHIFTING LANDSCAPE ACCELERATE AN AIDS VACCINE 5 How Can We Overcome Obstacles Years & Counting VIII Years and Counting: UNITED STATES CHINA HAITI DOMINICAN REPUBLIC U.S./PUERTO RICO JAMAICA I INDIA TRINIDAD & TOBAGO CAMEROON UGANDA RWANDA PERU THAILAND KENYA TANZANIA BRAZIL MALAWI ZAMBIA AIDS VACCINE ADVOCACY COALITION MAY 2 oo 2 Y E A R S & C O U N T I N G BOTSWANA SOUTH AFRICA AUSTRALIA A I D S VA C C I N E T R I A L S G E T T I N G T H E G L O B A L H O U S E I N O R D E R CIN ES SSR OAD S AC AC S V CRO AV AI AID HE AT T DS VA CC IN D EA VO CAC OA Y C LIT ION R E ss E T T I N G T H E AIDS Vaccines: The Next Frontiers 20 AVA C R e p o r t 06 C L O C K TURNING Piecing Together the HIV Prevention Puzzle AVAC Report 2009 THE PAGE Report 2010 AVA C R E P O R T : Research & Reality THE END PREVENTION on the Line ACHIEVING THE END One Year and Counting AVAC Report 2014/15 December 2015 REPORT 2012 w w w. a v a c. o r g
2 T W O D E C A D E S, O N E M E S S A G E : P R E V E N T I O N M AT T E R S When AVAC was founded in 1995, we were called the AIDS Vaccine Advocacy Coalition. Our singular goal was to advance swift, ethical research for a vaccine that was then and is today essential to bring the epidemic to a conclusive end. Twenty years later, AVAC is still focused on swift and ethical research, but our scope has expanded. Along with vaccines, we advocate for PrEP, microbicides, voluntary medical male circumcision, and more. And we ve evolved with the field. As positive results have delivered new tools, AVAC has led the charge for the rapid, strategic rollout of all options needed to end the epidemic. Through it all, our message has been the same: prevention is the center of the AIDS response. Not just any prevention but smart, evidence-based, community-owned, rights-based strategies. AVAC is the only advocacy group working across the full spectrum of biomedical prevention interventions, from early-stage research to large-scale rollout. We do this work because it s essential. We are able to do it because of our robust partnerships worldwide. We will keep doing it with your help until the epidemic has, finally, come to an end. AIDS VACCINES, HIV PREVENTION AND THE GLOBAL EPIDEMIC: A TIMELINE First US government trial held of preventive vaccine candidate The AIDS Service Organization (TASO) established in Uganda International Community of Women Living with HIV/AIDS founded First phase II AIDS vaccine trial begins, of two gp120 products First major syringe exchange program opens in the US Female condom receives approval from US FDA US Congress requires NIH and other agencies to expand involvement of women and minorities in all research US Public Health Service recommends AZT for pregnant women with HIV to reduce onward transmission
3 KEEPING THE FIELD ON TRACK N O M AT T E R W H AT. We ve experienced 20 years of breakthroughs and disappointments in prevention research. A vaccine that many had given up on was the first to provide modest protection. One microbicide everyone hoped for didn t pan out. Male circumcision and PrEP studies overcame skepticism and, together with antiretroviral therapy, paved the way for a prevention revolution. Through it all, AVAC has worked with partners to maintain the field s focus and press for continued research into an AIDS vaccine, a cure and more. Vaccine PrEP Combination Prevention Microbicides On Treatment Virally Suppressed Diagnosed Dx U Ending the AIDS epidemic takes comprehensive targets and action. Voluntary Medical Male Circumcision Contraceptive Methods Safe, Effective Harm Reduction Syringe Exchange Human Rights Cure UNAIDS formed Levine Committee calls for overhaul of NIH AIDS research International AIDS Vaccine Initiative (IAVI) formed First efficacy trials of VaxGen s AIDSVAX candidate start South Africa s Treatment Action Campaign founded The first protease inhibitor approved; effective HIV treatment now exists. AVAC co-founder Bill Snow publishes, Why We Need AIDS Vaccine Activism; AVAC founded the next month US President Bill Clinton announces goal of effective AIDS vaccine in 10 years UNAIDS estimates 16,000 new HIV transmissions each day South African AIDS Vaccine Initiative (SAAVI) established First African AIDS vaccine trial begins in Uganda
4 D E F I N I N G T H E P AT H FROM RESEARCH TO ROLLOUT. When AVAC was founded, the only biomedical HIV prevention options for adults were male and female condoms. The pathway for introducing any new strategy was largely unmapped. No one knew where the gaps would be between trial result and country action, between guidance and financial support. Now we do. Over two decades, AVAC has not only identified the gaps; we ve worked to bridge them, so that products reach people in programs that work without delay. Research to Rollout: A schematic road map Phase I Phase II/IIb Phase III Open-Label Extension / Post-Trial Access Demonstration Projects Product Introduction Scale Up Clinical Trial Safety and Efficacy Real-World Effectiveness For the first decade of AVAC s existence, most prevention advocacy focused on actions to the left of the red arrow above. But with results, come new challenges. We now work on research and on ensuring products cross the gap between efficacy and real-world use. Dale and Betty Bumpers Vaccine Research Center (VRC) opened at NIH Thousands march for global treatment access in Durban, South Africa IAVI, VRC and other leading laboratories and collaborators form Neutralizing Antibody Consortium first entity of its kind dedicated to solving this key scientific challenge facing field Eastern Europe and former Soviet Union reported to have highest rising rates of new infections in the world UN General Assembly convenes first ever special session on AIDS George W. Bush announces PEPFAR initiative Rationale for Global HIV Vaccine Enterprise laid out in Science
5 C R E AT I N G A G L O B A L N E T W O R K OF PREVENTION ADVOCATES. Twenty years ago, advocacy for HIV prevention hardly existed. So AVAC helped build a global network of advocates equipped with effective advocacy strategies and the latest evidence. With our support, they are putting prevention on the agenda in countries and communities around the globe. Partnering for a Prevention Revolution Through Advocacy Fellows, PxROAR members, coalition-building, strategic convening, training and other support, AVAC partners with stakeholders throughout the world to increase awareness and understanding of the current state of HIV prevention research and implementation. Together, we hold decision-makers accountable and press for smart investments and sound policies in all aspects of HIV prevention. Protests at Bangkok AIDS Conference target PrEP trials VaxGen Thai trial shows no efficacy Malawian government halts PrEP trial citing concerns about using ARVs for prevention Bill and Melinda Gates Foundation announces $287 million to support the Collaboration for AIDS Vaccine Discovery (CAVD) Kenyan and Ugandan trials confirm South African data showing voluntary medical male circumcision reduces HIV risk for HIV-negative men US FDA announces approval of Gardasil, which protects against strains of HPV that cause cervical cancer NIH convenes summit on HIV vaccine research with renewed emphasis on basic research Merck and HIV Vaccine Trials Network launch test of concept study of adenovirus-based vaccine Global HIV Vaccine Enterprise Scientific Strategic Plan published in PLoS Medicine Step and Phambili trials halted Merck s MRK-Ad5 vaccine shows no benefit and increased susceptibilty among some volunteers WHO recommends voluntary medical male circumcision for HIV prevention
6 D E M A N D I N G A C T I O N ON AN AGENDA TO END AIDS. When the world lacked a plan for ending AIDS, we helped create one. Now we re holding global leaders accountable for results demanding the resources, policies and evidencebased plans needed to deliver all of today s prevention options to the people who need them, and to plan for the rapid rollout of new options as they emerge. A Three-Part Agenda for Ending AIDS DELIVER proven tools for immediate impact DEMONSTRATE and roll out new HIV prevention options C O M B I N E GOAL: A sustained decline in HIV infections DEVELOP long-term solutions needed to end the epidemic Years to impact Zero to 5 5 to to End CAPRISA 004 trial of Tenofovir gel shows modest efficacy in South African women a first for microbicides iprex trial shows efficacy of dail oral PrEP in gay men and transgender women Pox Protein Public-Private Partnership (P5) established to build on results of RV144 US FDA approves daily Truvada as oral PrEP Analysis of RV144 results reveals two correlates of risk in participants Hundreds of broadly neutralizing antibodies IDed as possible targets for vaccine development RV144 trial of ALVAC/AIDSVAX shows modest 31.2% efficacy in preventing HIV acquisition first evidence of efficacy in any AIDS vaccine clinical trial HVTN 505 trial of DNA prime/ad5-boost vaccine begins South Africa begins massive expansion of ART program HPTN 052 trial shows treatment can reduce risk of transmission by up to 96% Partners PrEP trial shows high efficacy of daily oral PrEP in HIV-negative men and women in serodiscordant couples
7 MANAGING THROUGH CONTROVERSY. Communities support for prevention research can never be taken for granted it has to be earned. For 20 years, we ve helped build trust between researchers, funders and communities to speed the ethical development and rollout of new prevention options. And when controversy threatened to derail those efforts, AVAC provided leadership and resources to help get them back on track. The Good Participatory Practice (GPP) Guidelines provide trial funders, sponsors and implementers with systematic guidance on how to effectively engage with all stakeholders in the design and conduct of biomedical HIV prevention trials. Annual AIDS Vaccine Conference and biennial Microbicide Conference merge to become the HIV Research for Prevention Conference (HIV R4P), the first biomedical HIV prevention conference UNAIDS announces new goal for testing, treating and viral suppression; prevention and non-discrimination goals developed but not launched START trial stopped early, confirms individual health benefits of starting those living with HIV on antiretroviral therapy ART at CD4 cell counts above 350 WHO releases new recommendations: 1) Initiation of ART in all people living with HIV, regardless of CD4 cell count, and 2) Offer of PrEP as a prevention option to all people at substantial risk of acquiring HIV P5 outlines two proposed vaccine licensure trials one in Thailand and the other in South Africa and an additional research trial in Southern Africa HVTN 505 stops immunizations after DSMB finds trial cannot show efficacy ECHO trial to explore possible link between hormonal contraception and HIV acquisition FACTS 001 trial does not demonstrate efficacy of 1% tenofovir microbicide gel Two phase II trials of different longacting injectable ARVs launched
8 SUPPORTING OUR WORK Achieving the End of AIDS The world is talking about ending AIDS. AVAC s advocacy is dedicated to realizing that vision. To get there we must: Deliver proven tools for immediate impact. Demonstrate and roll out new HIV prevention tools. Develop long-term solutions to end the epidemic. Your gift to AVAC will support our efforts to accelerate the development and delivery of HIV prevention options to men and women worldwide. With your help, we can continue to convene, collaborate and communicate a strong, clear and cohesive vision for HIV prevention today, tomorrow and to end the epidemic. It will take all of us working together to end AIDS. Please join us. To learn more about AVAC, including our history, our focus and our team, please visit And to support this work, please go to West 127th Street 4th floor New York, NY USA T F E avac@avac.org W FOLLOW US ONLINE
May HIV Vaccines: The Basics
May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the
More informationTasP - Individual versus Public Health Benefit versus Both.
Site Map l Contact Us l Calendar l Join AVAC Donate TasP - Individual versus Public Health Benefit versus Both. Kevin Fisher Policy Director, AVAC June 2012 Multiple choice answer: all of the above We
More informationTowards a global HIV prevention coalition and road map. Preventing and reducing new HIV infections by 75% by 2020
Towards a global HIV prevention coalition and road map Preventing and reducing new HIV infections by 75% by 2020 Introduction United Nations Member States have committed to reducing new adult HIV infections
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationEnding the AIDS Epidemic in Adolescents
Ending the AIDS Epidemic in Adolescents Eastern and Southern Africa Regional Update on the ALL IN Overview 13 October 2015 AIDS-related deaths has declined for all age groups Except adolescents! Eastern
More informationFAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030
Evidence informed, responsive and sustainable care FAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030 Alti Zwandor UNAIDS Country Director Maseru, Lesotho 9 December
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationImpact of the Proposed Cuts to HIV/AIDS Research. Kevin Fisher AVAC September 7, 2017
Impact of the Proposed Cuts to HIV/AIDS Research Kevin Fisher AVAC September 7, 2017 President s FY18 Budget Cuts $544 m from the FY 2017 NIH HIV/AIDS research budget levels A cut of 18.5% FY 18 Cut FY
More informationThe Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014
The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase
More informationTowards an AIDS Free Generation
Informal Board Meeting 18 January, 2011 Towards an AIDS Free Generation Craig McClure Chief, HIV and AIDS Achieving an AIDS-Free Generation UNAIDS Getting to Zero UNICEF MTSP The Unite for Children, Unite
More informationETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationSuccessful results of clinical trials
Successful results of clinical trials Four clinical trials for HIV prevention in past two years showed different degrees of efficacy > HPTN 052 showed 96% reduction in HIV transmission from HIV infected
More informationHIV vaccine research and development
HIV vaccine research and development What is an HIV vaccine and how does it work? An HIV vaccine is a substance given to the body to teach it to defend itself against HIV. A successful preventative HIV
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationGLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW
GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW TOWARDS AN CURE PEOPLE FOCUSED SCIENCE DRIVEN JULY 2018 A GLOBAL STRATEGIC APPROACH TOWARDS
More informationLETTER TO PARTNERS 09
LETTER TO PARTNERS 09 SPEECH BY: Michel Sidibé, Executive Director of UNAIDS DATE: 17:00 18:30, 19 October 2009 PLACE: Marriott Rive Gauche Hotel and Conference Center, Paris France OCCASION: AIDS Vaccine
More informationProven strategies for today and research for tomorrow. A global source for updates, advocacy and information on biomedical HIV prevention.
Proven strategies for today and research for tomorrow. A global source for updates, advocacy and information on biomedical HIV prevention. Global Partners in Prevention Research Advocacy United States
More informationViiV Healthcare s Position on Prevention in HIV
ViiV Healthcare s Position on Prevention in HIV ViiV Healthcare is a company 100% committed to HIV, and we are always looking to move beyond the status quo and find new ways of navigating the challenges
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationThe outlook for hundreds of thousands adolescents is bleak.
Adolescents & AIDS Dr. Chewe Luo Chief HIV/AIDS, UNICEF Associate Director, Programmes Division 28/11/17 Professor Father Micheal Kelly Annual Lecture on HIV/AIDS Dublin, Ireland The outlook for hundreds
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationFinancial Resources for HIV: PEPFAR s Contributions to the Global Scale-up of Treatment
Financial Resources for HIV: PEPFAR s Contributions to the Global Scale-up of Treatment Joint WHO & UNAIDS Consultation with Pharmaceuticals and Stakeholders November 05 2012 Lara Stabinski, MD, MPH Medical
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationPlanned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
More informationUK Department for International Development: Joining forces in the development of new prevention technologies
Speech [Note: Check against delivery] UK Department for International Development: Joining forces in the development of new prevention technologies Challenges in combating the HIV epidemic, combination
More informationInternational Partnership for Microbicides. Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard
International Partnership for Microbicides Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard Dr. Zeda Rosenberg February 20, 2007 The Face of HIV Globally Increasingly
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationUnderstanding the results of CAPRISA 004
A Cascade of Hope and Questions Volume 2 Understanding the results of CAPRISA 004 Key messages CAPRISA 004 provides the first proof of concept that a microbicide (1% tenofovir gel) can reduce women s risk
More informationOverview of ARV-based prevention trials
Overview of ARV-based prevention trials Catherine Hankins BA MD MSc CCFP FRCPC Deputy Director, Science Amsterdam Institute for Global Health and Development; Department of Global Health, Academic Medical
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationAIDS Vaccines: The Next Frontiers. AVAC Report
AIDS Vaccines: The Next Frontiers AVAC Report 20 06 03. The Emerging Adolescent Agenda: HPV Vaccine, AIDS Prevention Research, and the New Opportunities for Reaching the Young People of the World Two years
More informationUPDATE UNAIDS 2016 DATE 2016
GLOBAL AIDS UP GLOBAL AIDS UPDATE UNAIDS 2016 DATE 2016 ENORMOUS GAINS, PERSISTENT CHALLENGES The world has committed to ending the AIDS epidemic by 2030. How to reach this bold target within the Sustainable
More informationWhat do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety
More informationBiomedical HIV Prevention & TaP Treatment as Prevention 2013
Biomedical HIV Prevention & TaP Treatment as Prevention 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationUpdate on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationCurrent State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationTRACKING FUNDING FOR MICROBICIDE RESEARCH & DEVELOPMENT:
TRACKING FUNDING FOR MICROBICIDE RESEARCH & DEVELOPMENT: ESTIMATES OF ANNUAL INVESTMENTS 2000 TO 2005 AUGUST 2005 HIV Vaccines and Microbicides Resource Tracking Working Group AIDS Vaccine Advocacy Coalition
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationA powerful new HIV prevention tool may be on the horizon. Are we prepared?
Ant i c i pat i n g th e Re s u lt s of PrEP Tr i a l s A powerful new HIV prevention tool may be on the horizon. Are we prepared? A publication from AVAC s Anticipating and Understanding Results series
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Advancing HIV Prevention Options for Women GNP+ Consultation on NPTs Thomas Mertenskoetter 5. 6. July 2010, Amsterdam Leading Causes of Death in Women (Age 15
More information2016 United Nations Political Declaration on Ending AIDS sets world on the Fast-Track to end the epidemic by 2030
S T A T E M E N T 2016 United Nations Political Declaration on Ending AIDS sets world on the Fast-Track to end the epidemic by 2030 World leaders commit to reach three goals and 20 new Fast-Track Targets
More informationSAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL
SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL Glenda Gray President & CEO SAMRC 1 SA AIDS 2017 Durban 15 June 2017 Partner logo LEADERSHIP IN A TIME OF UNCERTAINTY 2 BASELINE BUDGET
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationGlobal Collaboration on Cervical Cancer Prevention
Global Collaboration on Cervical Cancer Prevention Celina Schocken, JD, MBA, MPP Chief Executive Officer Presentation to the 2016 World Cancer Congress 1 November 2016 What Does Pink Ribbon Red Ribbon
More information10.4 Advocacy, Communication and Social Mobilization Working Group: summary strategic plan,
10.4 Advocacy, Communication and Social Mobilization Working Group: summary strategic plan, 2006 2015 Introduction A significant scaling-up of advocacy, communication and social mobilization for TB will
More informationHVTN 505 Study HIV Vaccine Candidate Not Effective
Subscribe Unsubscribe HVTN 505 Study HIV Vaccine Candidate Not Effective The National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network have announced there will be
More informationPartnerships between UNAIDS and the Faith-Based Community
Partnerships between UNAIDS and the Faith-Based Community Sally Smith- Partnership Adviser. Micah Network: Global Consultation-Churches Living with HIV Pattaya Thailand October 2008 UNAIDS Summary of 2008
More informationReview of planned trials and key emerging issues for Thailand
Review of planned trials and key emerging issues for Thailand Frits van Griensven, PhD, MPH Silom Community Clinic Thailand MOPH US CDC Collaboration US Centers for Disease Control and Prevention ilom
More informationProgress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa
SUMMARY REPORT Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa January December 2012 Table of contents List of acronyms 2 Introduction 3 Summary
More informationWorld Food Programme (WFP)
UNAIDS 2016 REPORT World Food Programme (WFP) Unified Budget Results and Accountability Framework (UBRAF) 2016-2021 2 Contents Achievements 2 Introduction 2 Innovative testing strategies 2 Access to treatment
More informationIFMSA Policy Statement Ending AIDS by 2030
IFMSA Policy Statement Ending AIDS by 2030 Proposed by IFMSA Team of Officials Puebla, Mexico, August 2016 Summary IFMSA currently acknowledges the HIV epidemic as a major threat, which needs to be tackled
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV
More informationUNAIDS 2016 THE AIDS EPIDEMIC CAN BE ENDED BY 2030 WITH YOUR HELP
UNAIDS 2016 THE AIDS EPIDEMIC CAN BE ENDED BY 2030 WITH YOUR HELP WHY UNAIDS NEEDS YOUR SUPPORT Over the past 35 years, HIV has changed the course of history. The massive global impact of AIDS in terms
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine
More informationSix things you need to know
UNAIDS Report 2010 MDG 6 Six things you need to know about the AIDS response today UNAIDS Report 2010 MDG 6 Six things you need to know about the AIDS response today MDG6: Combat HIV/AIDS, Malaria and
More informationThe Open Label Trial Past and Present
The Open Label Trial Past and Present Jared Baeten, M.D., Ph.D. University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention in
More informationViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV
ViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV ViiV Healthcare is a company 100% committed to HIV, and we are always looking to move beyond the status
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationHIV Prevention in Young People: Current Context, Opportunities and Challenges Dr. Susan Kasedde Senior Specialist, HIV Prevention UNICEF, NY
HIV Prevention in Young People: Current Context, Opportunities and Challenges Dr. Susan Kasedde Senior Specialist, HIV Prevention UNICEF, NY Web-Conference: Mass Media for HIV Prevention Among Young People
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationStatement by Dr Marcos Espinal at the ECOSOC High-Level Segment, 6 July Madam President, Esteemed Delegates, Ladies and Gentlemen.
Statement by Dr Marcos Espinal at the ECOSOC High-Level Segment, 6 July 2009 Madam President, Esteemed Delegates, Ladies and Gentlemen. Many thanks for the opportunity to speak here today. I think the
More informationUNAIDS 2013 AIDS by the numbers
UNAIDS 2013 AIDS by the numbers 33 % decrease in new HIV infections since 2001 29 % decrease in AIDS-related deaths (adults and children) since 2005 52 % decrease in new HIV infections in children since
More informationAdvancing the Science in a Time of Fiscal Constraint: Funding for HIV Prevention Technologies in 2009
Advancing the Science in a Time of Fiscal Constraint: Funding for HIV Prevention Technologies in 2009 July 2010 HIV Vaccines and Microbicides Resource Tracking Working Group www.hivresourcetracking.org
More informationGood Participatory Practice guidelines
Good Participatory Practice guidelines Prevention Research Advocacy Mentoring and Education Program (PRAMEP) 2 August 2008 Discussion: Is it important to have community representatives participate in the
More informationAbout FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.
Fact Sheet About FEM-PrEP What is the FEM-PrEP clinical trial? FEM-PrEP is a Phase III randomized, placebo-controlled, clinical trial designed to assess the safety and effectiveness of a daily oral dose
More informationWhere We Have Been and Where We are Going. Ian McGowan MD PhD FRCP
Where We Have Been and Where We are Going Ian McGowan MD PhD FRCP Directions Where we were Where we are headed Where we are 2005 The size of your dreams must always exceed your current capacity to achieve
More informationThe U.S. President s Emergency Plan for AIDS Relief (PEPFAR)
The U.S. President s Emergency Plan for AIDS Relief (PEPFAR) Although the U.S. has been involved in efforts to address the global AIDS crisis since the mid-1980s, the creation of the President s Emergency
More informationDescribe Key Features of the Research Context
4 Describe Key Features of the Research Context 35 Introduction In Step Three, you established a framework for monitoring and evaluating your stakeholder engagement efforts. In Step Four, you will identify
More informationHIV Prevention Research & Development Funding Trends, Investing in innovation in an evolving global health and development landscape
HIV Prevention Research & Development Funding Trends, 2000 Investing in innovation in an evolving global health and development landscape HIV Prevention Research & Development Funding Trends 2000 Investment
More informationNothing About Us Without Us! Community Engagement in HIV Research
Nothing About Us Without Us! Community Engagement in HIV Research Judith D. Auerbach, Ph.D. Professor, Center for AIDS Prevention Studies School of Medicine University of California, San Francisco Engaging
More informationWHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections
Common structure Universal Health Coverage SDGs Cascade of services Vision, Goals and Targets Costed Actions WHO Global Health Sector Strategies 2016-2021 HIV; Viral Hepatitis; Sexually Transmitted Infections
More informationAFRICAN AND BLACK DIASPORA GLOBAL NETWORK ON HIV AND AIDS ABDGN AIDS 2012 HIGHLIGHTS
AFRICAN AND BLACK DIASPORA GLOBAL NETWORK ON HIV AND AIDS ABDGN AIDS 2012 HIGHLIGHTS AGENDA Brief overview of ABDGN HIV and Migration Affiliated Event Black Diaspora Regional Working Group Black Diaspora
More informationADVOCACY IN UNCERTAIN TIMES. A call to action HIV VACCINE AWARENESS DAY MAY 18
ADVOCACY IN UNCERTAIN TIMES A call to action HIV VACCINE AWARENESS DAY 2017 MAY 18 2 HIV VACCINE AWARENESS DAY 2017 POLITICAL WILL A call to action These are hectic times. There is more information coming
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Female-Initiated Prevention: State of the Art Dr. Zeda F. Rosenberg German-Austrian AIDS Congress Frankfurt, Germany 29 June 2007 Women s Vulnerability to HIV
More informationA smart and doable investment
90-90-90 A smart and doable investment As of December 2013 Adults and children living with HIV Adults and children newly infected Adult & child deaths due to AIDS 35.0 million [33.2 million 37.2 million]
More informationLearning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda
Learning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda Pontiano Kaleebu MRC-UVRI Uganda Research Unit on AIDS & UVRI-IAVI HIV Vaccine Programme Past 1987 Cohort studies
More informationHIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative
HIV Viral Load Testing Market Analysis September 2012 Laboratory Services Team Clinton Health Access Initiative Agenda Background on Viral Load Testing Growth of Global Viral Load Market Factors Impacting
More informationThe Open Label Trial Past and Present
The Open Label Trial Past and Present Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention
More informationLessons learned from the IeDEA West Africa Collaboration
Lessons learned from the IeDEA West Africa Collaboration François DABIS with the contribution of Didier Koumavi EKOUEVI INSERM U-897, Bordeaux, France, Programme PACCI, ANRS site, Abidjan, Côte d Ivoire
More informationCopyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN
UNAIDS DATA TABLES 2011 Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN 978-92-9173-945-5 UNAIDS / JC2225E The designations employed and the presentation of
More informationHP+/Project SOAR Oral PrEP Modeling. Webinar Series: Five Ways to Accelerate Progress Toward the Goals January 16, 2018
HP+/Project SOAR Oral PrEP Modeling Webinar Series: Five Ways to Accelerate Progress Toward the 95-95-95 Goals January 16, 2018 Activity Overview 2 Activity Objective Provide impact, cost, and cost-effectiveness
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationOperations Research to Advance Scale-Up of HIV/ AIDS Programmes: What is the Way Forward?
Operations Research to Advance Scale-Up of HIV/ AIDS Programmes: What is the Way Forward? Report of a special session convened by the International AIDS Society with support from the Doris Duke Charitable
More informationProgress Report: Universal Access Target Setting in East and Southern Africa
Progress Report: Universal Access Target Setting in East and Report prepared by: Team for East & 15 September 2006 For all inquiries please contact Mark Stirling, Regional Director for Eastern and, at
More information2020 Vision: making England s HIV prevention response the best in the world
DISCUSSION PAPER 2020 Vision: making England s HIV prevention response the best in the world Introduction Effective HIV prevention makes good public health and economic sense. HIV remains one of the fastest-growing
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationProgram to control HIV/AIDS
90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,
More informationAntiretrovirals for HIV prevention:
Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited
More informationTranslating the Science to End New HIV Infections in Kenya
Translating the Science to End New HIV Infections in Kenya Perspectives, Practices and Lessons Nairobi, 28-30 May 2017 www.iasociety.org AIDS 2016 Post-Conference Workshop Setting the Stage Overview of
More informationThresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016
Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016 1 Objectives of today s lecture Describe global goals in the fight against HIV Review the epidemiology
More informationBiomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013
Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationPromoting FP/RH-HIV/AIDS Integration: A Summary of Global Health Initiative Strategies in Ethiopia, Kenya, Tanzania, and Zambia
Promoting FP/RH-HIV/AIDS Integration: A Summary of Global Health Initiative Strategies in Ethiopia, Kenya, Tanzania, and Zambia The Global Health Initiative (GHI) is an integrated approach to global health
More information